Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same author

TQC3721: Expanding the Role of Dual Phosphodiesterase 3/4 Inhibition in COPD Management.

Chest·2026
Same author

Mucus plugs in COPD and cardiovascular mortality: An emerging risk pathway and the therapeutic potential of mucolytic strategies.

Respiratory medicine·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.

Expert review of respiratory medicine·2026
Same author

Redox signaling in chronic airway diseases: pathogenic mechanisms and therapeutic implications.

Frontiers in physiology·2026

Related Experiment Video

Updated: May 3, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Bronchodilators: current and future.

Mario Cazzola1, Maria Gabriella Matera2

  • 1Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy.

Clinics in Chest Medicine
|February 11, 2014
PubMed
Summary
This summary is machine-generated.

Bronchodilators are key for managing chronic obstructive pulmonary disease (COPD) symptoms. Novel dual-acting bronchodilator molecules, combining corticosteroid and bronchodilator effects, show promise for improved COPD treatment efficacy.

Keywords:
Antimuscarinic agentsChoice of bronchodilatorsChronic obstructive pulmonary diseaseEmerging bronchodilatorsMethylxanthinesβ(2)-Agonists

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

629

Related Experiment Videos

Last Updated: May 3, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

629

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Bronchodilators are essential for symptomatic relief in chronic obstructive pulmonary disease (COPD).
  • Current bronchodilator classes (β2-agonists, antimuscarinic agents, methylxanthines) offer limited reversibility of airflow obstruction.
  • Development of novel bronchodilator classes for COPD has been challenging.

Purpose of the Study:

  • To explore the potential of novel bronchodilator approaches for COPD treatment.
  • To investigate the development of combination therapies with enhanced efficacy.
  • To identify promising molecular strategies for future COPD pharmacotherapy.

Main Methods:

  • Review of current bronchodilator classes and their limitations in COPD.
  • Analysis of emerging molecular targets and drug design strategies.
  • Evaluation of combination therapy principles in respiratory diseases.

Main Results:

  • Existing bronchodilators provide symptomatic relief but often with incomplete airflow reversibility.
  • Development of new bronchodilator classes remains a significant hurdle.
  • Muscarinic β2-agonist molecules present a viable strategy for dual bronchodilator activity.

Conclusions:

  • Novel combination therapies are needed to improve COPD management.
  • Dual-acting bronchodilators, particularly those combining corticosteroid and bronchodilator effects, offer a promising avenue.
  • The muscarinic β2-agonist approach may lead to more effective COPD treatments than current options.